AstraZeneca plc (NYSE: AZN) reported third‑quarter 2026 worldwide revenue of USD 16.21 billion, up 7% year‑on‑year, driven by strong growth in oncology, respiratory and immunology, and rare disease treatments. The company maintained its full‑year guidance for mid‑to‑high single‑digit revenue growth and low double‑digit core earnings per share (EPS) growth at constant exchange rates (CER).
Expanding use across lung, gastrointestinal, and genitourinary cancers
Calquence (acalabrutinib)
USD 1.07 bn
+16%
Hematology franchise
Enhertu (trastuzumab deruxtecan)
USD 969 mn
+36%
Includes AstraZeneca’s share of alliance revenue
Datroway (datopotamab deruxtecan)
USD 78 mn
More than tripled
Newer oncology launch
Etcamah (camizestrant)
USD 7 mn
New launch
Recently launched breast cancer treatment
Fasenra (benralizumab)
USD 602 mn
+13%
Respiratory & immunology
Tezspire (tezepelumab)
USD 429 mn
+50%
Led respiratory & immunology growth
Ultomiris (ravulizumab)
USD 1.43 bn
+17%
Rare disease
Strensiq (asfotase alfa)
USD 588 mn
+33%
Rare disease
Farxiga (dapagliflozin)
USD 1.61 bn
−25%
U.S. loss of exclusivity and China VBP pressure
Brilinta (ticagrelor)
USD 75 mn
−48%
Generic competition and pricing pressure
Geographic Revenue
Region
Q3 2026 Revenue
YoY Change
United States
USD 6.9 bn
+5%
Europe
USD 3.71 bn
+11%
Emerging Markets (total)
USD 4.2 bn
+6%
China
USD 1.92 bn
+9% (+3% CER)
Emerging ex‑China
USD 2.28 bn
+4%
Established Rest of World
USD 1.41 bn
+4%
China – Revenue Rises 9% Despite Procurement Pressures
Quarterly Performance:China revenue increased 9% year‑on‑year to USD 1.92 billion (equivalent to 3% growth at CER); first‑nine‑month revenue reached USD 5.43 billion, up 3% in reported terms but down 3% at CER, reflecting continuing pricing and competitive pressures.
Headwinds: The China business remained affected by volume‑based procurement (VBP)–related price reductions and generic competition, particularly for Farxiga and Lynparza (olaparib); AstraZeneca also cited a more competitive market for Tagrisso, though newer products provided offsetting growth.
Reimbursement Tailwinds: Asthma treatment Fasenra benefited from increased uptake following its inclusion on China’s National Reimbursement Drug List (NRDL) in Q1 2026, while respiratory therapy Breztri (budesonide/glycopyrronium/formoterol) continued to gain market share.
Oncology Expansion: AstraZeneca secured additional approvals for Enhertu and Datroway in China during the quarter.
Dizal Deal Completed: The company completed its licensing agreement with China’s Dizal Pharmaceutical in August for Zegfrovy (sunvozertinib), an EGFR inhibitor approved in China and the U.S. for previously treated EGFR exon 20 insertion–mutated non‑small cell lung cancer.
Market Impact & Outlook
Oncology Engine Intact: With 48% of sales and 17% growth, oncology – led by Imfinzi (+24%) and Enhertu (+36%) – remains the structural core of AstraZeneca’s growth story.
Launch Portfolio Ramping:Datroway more than tripling and early Etcamah contributions signal the next oncology wave beginning to scale.
Guidance Confidence: Management maintained full‑year guidance, implying conviction that new‑launch momentum offsets Farxiga and Brilinta erosion from loss of exclusivity and VBP.
China Stabilization: The 9% reported rebound in Q3, NRDL‑driven Fasenra uptake, Breztri share gains, and new oncology approvals suggest the China business is stabilizing despite VBP‑related pricing drag.
Pipeline Depth: The completed Zegfrovy (sunvozertinib) license from Dizal adds a differentiated EGFR exon20ins asset approved in both major markets.
Forward‑Looking Statements This brief contains forward‑looking statements regarding AstraZeneca’s revenue guidance, core EPS growth, product launches, regulatory approvals, and China market performance. Actual results may differ materially due to risks including foreign‑exchange fluctuations, generic competition, volume‑based procurement pricing, regulatory outcomes, and commercialization execution. Figures are as reported in the company’s Q3 2026 results; growth rates are year‑on‑year and stated at constant exchange rates (CER) where indicated.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
